Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Moodys
Johnson and Johnson
AstraZeneca
Boehringer Ingelheim

Last Updated: May 31, 2023

Xspire Pharma Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Xspire Pharma
International Patents:155
US Patents:2
Tradenames:6
Ingredients:5
NDAs:6

Drugs and US Patents for Xspire Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-003 Approved Prior to Jan 1, 1982 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Xspire Pharma FENOPROFEN CALCIUM fenoprofen calcium TABLET;ORAL 072267-001 Aug 17, 1988 RX No Yes ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Xspire Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Xspire Pharma ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 7,235,567 ⤷  Try a Trial
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-003 Approved Prior to Jan 1, 1982 3,600,437 ⤷  Try a Trial
Xspire Pharma NALFON fenoprofen calcium CAPSULE;ORAL 017604-002 Approved Prior to Jan 1, 1982 3,600,437 ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Xspire Pharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1429780 13C0012 France ⤷  Try a Trial PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1495018 15C0047 France ⤷  Try a Trial PRODUCT NAME: VORAPAXAR,OU L'UN DE SES SELS OU SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/14/976/001-006 20150121
1495018 C01495018/01 Switzerland ⤷  Try a Trial PRODUCT NAME: VORAPAXAR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65803 19.09.2016
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKinsey
Boehringer Ingelheim
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.